Medicare Enrolled
Dr. Emily Nagler, MD
Hospitalist Physician · La Jolla, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nagler from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nagler?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nagler
Dr. Emily Nagler is a hospitalist physician in La Jolla, CA, with 12 years of NPI registration. Based on federal Medicare data, Dr. Nagler performed 5,875 Medicare services across 833 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nagler received a total of $31,516 from 77 pharmaceutical and/or device companies across 559 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hospitalist physician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nagler is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice
▲ Top 1% volume in CA
$31,516 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,875
Medicare services
Top 1% in CA for hospitalist physician
833
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~490 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 3,380 | $1 | $7 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
640 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 530 | $0 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
273 | $142 | $491 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
234 | $103 | $350 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
168 | $14 | $55 |
| New patient office visit, complex (60-74 min) | 144 | $166 | $598 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
126 | $6 | $37 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
107 | $120 | $479 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
74 | $55 | $236 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
58 | $98 | $269 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
40 | $25 | $100 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
35 | $8 | $27 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
34 | $12 | $46 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
32 | $59 | $232 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.6% high complexity
83.7% medium
12.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$31,516
Total received (2018-2024)
Avg $4,502/year across 7 years
Top 1% in CA for hospitalist physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
77
Companies
559
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$13,868 (44.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,657 (40.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,991 (15.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$15,362
2023
$6,636
2022
$2,036
2021
$1,320
2020
$1,592
2019
$2,481
2018
$2,089
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PharmaEssentia USA Corporation
$10,534
Agios Pharmaceuticals, Inc.
$1,992
Alexion Pharmaceuticals, Inc.
$391
SOBI, INC
$341
Novartis Pharmaceuticals Corporation
$282
GlaxoSmithKline, LLC.
$178
Eisai Inc.
$176
ABBVIE INC.
$166
Janssen Biotech, Inc.
$138
AstraZeneca Pharmaceuticals LP
$114
Regeneron Healthcare Solutions, Inc.
$92
Kite Pharma, Inc.
$90
Merck Sharp & Dohme LLC
$89
Deciphera Pharmaceuticals Inc.
$87
Celgene Corporation
$86
Bayer Healthcare Pharmaceuticals Inc.
$83
Incyte Corporation
$70
ARRAY BIOPHARMA INC
$63
PUMA BIOTECHNOLOGY, INC.
$54
PFIZER INC.
$41
Daiichi Sankyo Inc.
$40
SERVIER PHARMACEUTICALS LLC
$39
Gilead Sciences, Inc.
$31
TAIHO ONCOLOGY, INC.
$29
Stemline Therapeutics Inc.
$26
Genentech USA, Inc.
$25
SpringWorks Therapeutics, Inc.
$25
BeiGene USA, Inc.
$24
Ipsen Biopharmaceuticals, Inc
$23
Lilly USA, LLC
$19
Sumitomo Pharma America, Inc.
$15
Top 3 companies account for 84.1% of 2024 payments
All-time payments by company (2018-2024) ›
PharmaEssentia USA Corporation
$12,656
Agios Pharmaceuticals, Inc.
$2,863
SOBI, INC
$2,701
GlaxoSmithKline, LLC.
$1,253
Novartis Pharmaceuticals Corporation
$1,066
AstraZeneca Pharmaceuticals LP
$1,026
Alexion Pharmaceuticals, Inc.
$853
Amgen Inc.
$766
Merck Sharp & Dohme Corporation
$621
Celgene Corporation
$505
Incyte Corporation
$377
Daiichi Sankyo Inc.
$350
Astellas Pharma US Inc
$347
Janssen Biotech, Inc.
$300
Gilead Sciences, Inc.
$288
Genentech USA, Inc.
$277
ABBVIE INC.
$267
BeiGene USA, Inc.
$213
E.R. Squibb & Sons, L.L.C.
$212
Pharmacyclics LLC, An AbbVie Company
$212
Eisai Inc.
$211
PFIZER INC.
$211
Puma Biotechnology, Inc.
$211
Kite Pharma, Inc.
$205
Seagen Inc.
$188
AbbVie, Inc.
$179
GENZYME CORPORATION
$173
Blueprint Medicines Corporation
$169
Regeneron Healthcare Solutions, Inc.
$155
Janssen Scientific Affairs, LLC
$147
Pharmacyclics LLC, an AbbVie Company
$141
Ipsen Biopharmaceuticals, Inc
$132
Bayer Healthcare Pharmaceuticals Inc.
$127
Aurobindo Pharma USA, Inc.
$125
Exelixis Inc.
$114
Deciphera Pharmaceuticals Inc.
$111
Lilly USA, LLC
$107
Merck Sharp & Dohme LLC
$89
Kyowa Kirin, Inc.
$82
ARRAY BIOPHARMA INC
$80
EMD Serono, Inc.
$79
PUMA BIOTECHNOLOGY, INC.
$78
Stemline Therapeutics Inc.
$77
Dova Pharmaceuticals
$72
AVEO Pharmaceuticals, Inc.
$72
Janssen Pharmaceuticals, Inc
$69
G1 Therapeutics, Inc.
$66
Foundation Medicine, Inc.
$60
TerSera Therapeutics LLC
$60
TAIHO ONCOLOGY, INC.
$57
Clovis Oncology, Inc.
$54
Rigel Pharmaceuticals, Inc.
$51
AMAG Pharmaceuticals, Inc.
$49
Bayer HealthCare Pharmaceuticals Inc.
$43
Takeda Pharmaceuticals U.S.A., Inc.
$42
SERVIER PHARMACEUTICALS LLC
$39
Genmab U.S., Inc.
$36
Otsuka America Pharmaceutical, Inc.
$32
Apellis Pharmaceuticals, Inc.
$30
Seattle Genetics, Inc.
$30
SANOFI-AVENTIS U.S. LLC
$28
AbbVie Inc.
$26
SpringWorks Therapeutics, Inc.
$25
Taiho Oncology, Inc.
$24
CSL Behring
$23
ADC Therapeutics America, Inc.
$21
Mirati Therapeutics, Inc.
$19
Sobi, Inc
$18
Boehringer Ingelheim Pharmaceuticals, Inc.
$17
Karyopharm Therapeutics Inc.
$16
TESARO, Inc.
$16
Sumitomo Pharma America, Inc.
$15
Sirtex Medical Inc
$15
INSYS Therapeutics Inc
$14
EISAI INC.
$13
Jazz Pharmaceuticals Inc.
$12
Secura Bio, Inc.
$7
Top 3 companies account for 57.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Abraxane · Alecensa · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Beleodaq · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · CREON · CRESEMBA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Empaveli · Enhertu · Epkinly · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · Farydak · GAVRETO · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUTATHERA · LYNPARZA · Lenvima · MONJUVI · MYLOTARG · NERLYNX · NINLARO · NOXAFIL · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PREVYMIS · PROMACTA · PYRUKYND · Pomalyst · QINLOCK · Quzyttir · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rubraca · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · TREMFYA · TUKYSA · Tavalisse · Tibsovo · Turalio · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vanflyta · Vectibix · Venclexta · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · Xermelo · Xofigo · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (44%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 1% for hospitalist physician in CA.
Geographic Context
Hospitalist physicians within 10 mi
179
Per 100K population
5.5
County median income
$102,285
Nearest hospital
SCRIPPS MEMORIAL HOSPITAL LA JOLLA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nagler is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with consulting-driven industry engagement in the top 1% of CA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nagler experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Nagler performed 3,380 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nagler receive payments from pharmaceutical companies?
Yes. Dr. Nagler received a total of $31,516 from 77 companies across 559 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nagler's costs compare to other hospitalist physicians in La Jolla?
Dr. Nagler's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nagler) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hospitalist Physicians in La Jolla
Browse hospitalist physicians in La Jolla ranked by procedure volume and transparency data.
Highest volume
Top Hospitalist Physicians in CA
Hospitalist physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hospitalist Physicians in CA
Which CA hospitalist physicians receive the most from drug and device companies.
By company
PharmaEssentia USA Corporation Payments to Doctors
See all physicians who received payments from PharmaEssentia USA Corporation.
By company
Agios Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Agios Pharmaceuticals, Inc.
By company
SOBI, INC Payments to Doctors
See all physicians who received payments from SOBI, INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology